Pascolizumab（Cat No.:I042085）is an investigational monoclonal antibody targeting the protein IL-6R (interleukin-6 receptor), a key player in inflammation and immune responses. IL-6R activation is involved in various autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus (SLE), and certain cancers. By blocking IL-6R, pascolizumab aims to reduce inflammation and regulate immune responses, potentially alleviating symptoms of these conditions. It is being evaluated in clinical trials for its safety, efficacy, and potential to provide therapeutic benefits in inflammatory and autoimmune diseases, either as a monotherapy or in combination with other treatments.
